BACKGROUND: The aim of this retrospective population-based study, which was conducted before the introduction of imatinib, was to evaluate the role of surgery in patients with gastrointestinal stromal tumours (GISTs) and clarify which subgroups might benefit from adjuvant treatment. METHODS: Two hundred and fifty-nine patients with clinically detected GISTs were studied. Univariate and multivariate analyses were performed to identify predictors for recurrent disease and survival. RESULTS: Thirty of 48 patients with high-risk GISTs and all of those with overtly malignant tumours developed recurrent tumour after complete (R0) resection. Thirty-four of 38 first recurrences occurred within 36 months of surgery. No recurrence was observed after 72 months. R0 resection, achieved in 48 (80 per cent) of 60 patients with high-risk tumours, was significantly associated with a decreased risk of death from tumour recurrence (P = 0.008). CONCLUSION: Completeness of surgical resection is an independent prognostic factor in patients with high-risk GISTs. A period of adjuvant treatment with imatinib is recommended in patients with high-risk or overtly malignant GISTs who have undergone R0 resection and have a tumour-free interval of less than 6 years. Copyright 2006 British Journal of Surgery Society Ltd.
BACKGROUND: The aim of this retrospective population-based study, which was conducted before the introduction of imatinib, was to evaluate the role of surgery in patients with gastrointestinal stromal tumours (GISTs) and clarify which subgroups might benefit from adjuvant treatment. METHODS: Two hundred and fifty-nine patients with clinically detected GISTs were studied. Univariate and multivariate analyses were performed to identify predictors for recurrent disease and survival. RESULTS: Thirty of 48 patients with high-risk GISTs and all of those with overtly malignant tumours developed recurrent tumour after complete (R0) resection. Thirty-four of 38 first recurrences occurred within 36 months of surgery. No recurrence was observed after 72 months. R0 resection, achieved in 48 (80 per cent) of 60 patients with high-risk tumours, was significantly associated with a decreased risk of death from tumour recurrence (P = 0.008). CONCLUSION: Completeness of surgical resection is an independent prognostic factor in patients with high-risk GISTs. A period of adjuvant treatment with imatinib is recommended in patients with high-risk or overtly malignant GISTs who have undergone R0 resection and have a tumour-free interval of less than 6 years. Copyright 2006 British Journal of Surgery Society Ltd.
Authors: António M Gouveia; Amadeu P Pimenta; Ana F Capelinha; Dionísio de la Cruz; Paula Silva; José M Lopes Journal: World J Surg Date: 2008-11 Impact factor: 3.352
Authors: Jason S Gold; Mithat Gönen; Antonio Gutiérrez; Javier Martín Broto; Xavier García-del-Muro; Thomas C Smyrk; Robert G Maki; Samuel Singer; Murray F Brennan; Cristina R Antonescu; John H Donohue; Ronald P DeMatteo Journal: Lancet Oncol Date: 2009-09-28 Impact factor: 41.316
Authors: Ahmet Fikret Yucel; Haldun Sunar; Adnan Hut; Ahmet Kocakusak; Ahmet Pergel; Gul Barut; Suleyman Dikici Journal: Case Rep Gastroenterol Date: 2010-07-26
Authors: Antonio Chiappa; Andrew P Zbar; Michael Innis; Stuart Garriques; Emilio Bertani; Roberto Biffi; Giancarlo Pruneri; Felipe Luzzato; Paolo Della Vigna; Cristina Trovato; Bruno Andreoni Journal: World J Surg Oncol Date: 2006-10-09 Impact factor: 2.754
Authors: B Nilsson; K Sjölund; L-G Kindblom; J M Meis-Kindblom; P Bümming; O Nilsson; J Andersson; H Ahlman Journal: Br J Cancer Date: 2007-05-29 Impact factor: 7.640